Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18790933 | Novel Retinitis Pigmentosa Treatment | July 2024 | February 2026 | Allow | 18 | 4 | 1 | Yes | No |
| 18020728 | GENE FUSIONS FOR CONTROL OF GENETICALLY MODIFIED CELLS | February 2023 | February 2026 | Allow | 36 | 1 | 0 | No | No |
| 18068594 | Bio-control methods for Xylella and Xanthomonas Bacteria | December 2022 | March 2026 | Abandon | 39 | 0 | 1 | No | No |
| 18054431 | CIRCULAR RNA PLATFORMS, USES THEREOF, AND THEIR MANUFACTURING PROCESSES FROM ENGINEERED DNA | November 2022 | November 2025 | Allow | 36 | 2 | 1 | No | No |
| 18048382 | METHODS AND COMPOSITIONS FOR TREATING ACUTE MYELOID LEUKEMIA | October 2022 | February 2026 | Abandon | 40 | 2 | 0 | No | No |
| 17907302 | DE NOVO DESIGNED ALPHA-HELICAL PROTEIN CHANNELS | September 2022 | March 2026 | Abandon | 41 | 1 | 0 | No | No |
| 17934796 | PRODRUG INCORPORATED sgRNA SYNTHESIS | September 2022 | January 2026 | Abandon | 40 | 0 | 1 | No | No |
| 17797700 | GENE EDITING METHODS FOR TREATING SPINAL MUSCULAR ATROPHY | August 2022 | December 2025 | Allow | 40 | 2 | 1 | No | No |
| 17842983 | METHODS AND COMPOSITIONS FOR TREATING CANCER | June 2022 | February 2026 | Abandon | 44 | 1 | 0 | No | No |
| 17777690 | TREATMENT OF HEREDITARY ANGIOEDEMA WITH LIVER-SPECIFIC GENE THERAPY VECTORS | May 2022 | January 2026 | Abandon | 44 | 0 | 1 | No | No |
| 17771128 | BASE EDITOR-MEDIATED CD33 REDUCTION TO SELECTIVELY PROTECT THERAPEUTIC CELLS | April 2022 | October 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17765080 | COMPOSITIONS AND METHODS FOR SILENCING UGT1A1 GENE EXPRESSION | March 2022 | August 2025 | Allow | 41 | 0 | 1 | Yes | No |
| 17763303 | ANTI-MIRNAS FOR THE TREATMENT OF LEIOMYOMA | March 2022 | November 2025 | Abandon | 44 | 1 | 0 | No | No |
| 17753927 | NUCLEIC ACID MOLECULE FOR TREATING THROMBOCYTOPENIA AND APPLICATION THEREOF | March 2022 | November 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17681177 | ENGINEERED EXOSOMES FOR TARGETED DELIVERY | February 2022 | November 2025 | Abandon | 44 | 1 | 0 | No | No |
| 17636754 | SKELETAL MYOBLAST PROGENITOR CELL LINEAGE SPECIFICATION BY CRISPR/CAS9-BASED TRANSCRIPTIONAL ACTIVATORS | February 2022 | February 2026 | Allow | 47 | 2 | 1 | Yes | No |
| 17649781 | METHODS FOR TREATING HEPATITIS B INFECTION | February 2022 | October 2025 | Allow | 45 | 2 | 0 | No | No |
| 17614495 | Novel Retinitis Pigmentosa Treatment | November 2021 | October 2025 | Allow | 47 | 2 | 0 | No | No |
| 17595621 | NUCLEIC ACID, PHARMACEUTICAL COMPOSITION, CONJUGATE, PREPARATION METHOD, AND USE | November 2021 | January 2026 | Allow | 49 | 2 | 1 | No | No |
| 17602313 | CAS13 FAMILY AAV VECTORS AND USES THEREOF | October 2021 | September 2025 | Allow | 48 | 1 | 0 | No | No |
| 17311675 | BACILLUS EXPRESSION SYSTEM | June 2021 | September 2025 | Allow | 52 | 1 | 1 | No | No |
No appeal data available for this record. This may indicate that no appeals have been filed or decided for applications in this dataset.
Examiner ALLEN, SARAH ELIZABETH works in Art Unit 1637 and has examined 4 patent applications in our dataset. With an allowance rate of 100.0%, this examiner allows applications at a higher rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 49 months.
Examiner ALLEN, SARAH ELIZABETH's allowance rate of 100.0% places them in the 94% percentile among all USPTO examiners. This examiner is more likely to allow applications than most examiners at the USPTO.
On average, applications examined by ALLEN, SARAH ELIZABETH receive 1.50 office actions before reaching final disposition. This places the examiner in the 26% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by ALLEN, SARAH ELIZABETH is 49 months. This places the examiner in the 6% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
When applicants file an RCE with this examiner, 50.0% of applications are subsequently allowed. This success rate is in the 96% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 50.0% of cases where such amendments are filed. This entry rate is in the 74% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 2% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.